New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
Accepting patients
EXCALIBER - Maintenance
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
- CELMoD
- Post-Autologous Stem Cell Transplant
- Randomization
- Phase 3
Accepting patients
LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1/2
- Has results
Accepting patients
DURGA-2
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma
- CAR T Cell
- BCMA
- CD19
- High Risk
- Phase 1
Accepting patients
SIM0500
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
- Trispecific Antibody
- GPRC5D
- BCMA
- Phase 1